Assuta Medical Center
| Israele | Turchia | Austria | |
| Terapia con Bacillo di Calmette-Guérin (BCG) | - | da $1,200 | da $2,400 |
Giorno 1: Arrivo
Giorno 2: Fase pre-operatoria
Giorno 3: Terapia con Bacillo di Calmette-Guérin (BCG)
Giorno 4-6: Post-intervento
Settimana 1-4: Riabilitazione
Si prega di notare che l'esperienza di ogni paziente con la terapia BCG può variare in base alle condizioni di salute individuali e alla natura specifica della patologia.
Il Prof. Merimsky dirige l'Unità di Oncologia del Tessuto Molle e Osseo presso il Centro Medico Sourasky, specializzata nella terapia BCG per casi complessi.
Il Dr. Raphael conduce rivoluzionarie sperimentazioni cliniche in oncologia presso il Centro Medico Sourasky, inclusa la ricerca pionieristica sulla terapia BCG.
Dr. Yaacov Lawrence, MA, MBBS, MRCP, is Chair of Radiation Oncology at Sheba Medical Center. He has nearly 30 years of experience in precision radiation oncology and neuro-oncology.
He is an expert in advanced radiation therapy and radiosurgery. He performs stereotactic radiosurgery for brain tumors. He leads Sheba’s GI Cancer Program in gastrointestinal oncology. He also provides precision care for lung and prostate cancers. He pioneered celiac plexus radiosurgery for severe pain from pancreatic cancer.
Training and credentials: MA and MBBS (Cambridge and UCLH); MRCP (RCP); Radiation Oncology fellowship (Thomas Jefferson University). Honors include the ASCO Young Investigator Award and Fellow of ASTRO (FASTRO). He has authored over 280 publications. He is Director of the Center for Translational Radiation Oncology and an Associate Professor at Tel Aviv University.
Dr. Nir Kleinmann, MD, directs the Endourology and Kidney Stones Unit at Sheba Medical Center. He is an expert in minimally invasive urology and urologic oncology. His focus is the kidney and upper urinary tract. He was named among Israel’s Best Doctors for 2025–2026 by Forbes and ResultMed.
He is a pioneer of kidney‑sparing laser surgery. He uses a dual‑laser system with neodymium and holmium for complex tumors. His expertise includes UTUC, kidney and prostate cancer, kidney stones, and BPH.
His research includes the OLYMPUS trial on chemoablation for UTUC. He has more than 60 publications.
He is an Israeli board‑certified urologist. He is a Fellow of the American Endourology Society and a member of the Israeli Urological Association and the EAU. He completed fellowships in Endourology and Minimally Invasive Surgery at Thomas Jefferson University. He also completed a fellowship in Kidney Cancer Research at McMaster University.